Current status and evolution of preclinical drug development models of epithelial ovarian cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades have significantly improved the median survival...
Main Authors: | Panagiotis A Konstantinopoulos, Ursula A Matulonis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00296/full |
Similar Items
-
Harnessing preclinical models for the interrogation of ovarian cancer
by: Tianyu Qin, et al.
Published: (2022-09-01) -
Preclinical models in radiation oncology
by: Kahn Jenna, et al.
Published: (2012-12-01) -
The Validation of a Precursor Lesion of Epithelial Ovarian Cancer in <i>Fancd2-</i>KO Mice
by: Sarah Sczelecki, et al.
Published: (2023-05-01) -
Preclinical Models of Visceral Sarcomas
by: Alice Costa, et al.
Published: (2023-11-01) -
Luciferase Expressing Preclinical Model Systems Representing the Different Molecular Subtypes of Colorectal Cancer
by: Arne Rotermund, et al.
Published: (2023-08-01)